Late Endocrine and Organ Toxicities After Treosulfan‐Based Conditioning in Pediatric Hematopoietic Cell Transplantation: A Systematic Review
- 10 September 2026
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
Abstract
Treosulfan is an alkylating agent indicated as a conditioning agent for allogeneic hematopoietic cell transplantation (HCT), with an established favorable acute toxicity profile; however, its long‐term sequelae remain incompletely characterized. This review aims to characterize the late effects following treosulfan‐based conditioning in pediatric HCT and to identify critical gaps in published evidence. This systematic review was conducted in accordance with PRISMA guidelines and prospectively registered with PROSPERO (CRD420261345072). PubMed, Embase, and the Cochrane Library were searched from inception through April 28, 2026 for studies reporting late effects in patients aged ≤ 40 years at the time of HCT who received treosulfan‐based conditioning. Risk of bias was assessed using the Newcastle–Ottawa Scale. Sixteen retrospective studies met inclusion criteria. Three studies evaluated sex hormone replacement therapy, and none of the patients receiving treosulfan required it. Treosulfan use was associated with significantly less gonadal toxicity compared to busulfan in several cohorts. Non‐gonadal endocrine or non‐endocrine late effects were reported mostly in single cohorts with no significant differences compared to busulfan. In conclusion, treosulfan‐based conditioning appears to have a meaningfully lower risk to gonadal dysfunction compared to busulfan, most prominently in patients with nonmalignant diagnoses and in females. No significant differences were observed for non‐gonadal late effects, albeit data remain limited.Keywords
This publication has 42 references indexed in Scilit:
- Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantationPediatric Blood & Cancer, 2023
- Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell TransplantTransplantation and Cellular Therapy, 2019
- Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevanceEuropean Journal of Pharmaceutical Sciences, 2017
- Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of AgeTransplantation and Cellular Therapy, 2017
- Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationCancer, 2017
- Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter TrialTransplantation and Cellular Therapy, 2014
- Prevalence of Hematopoietic Cell Transplant Survivors in the United StatesTransplantation and Cellular Therapy, 2013
- The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor studyPediatric Blood & Cancer, 2013
- Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)Transplantation and Cellular Therapy, 2011
- Myeloablative and immunosuppressive properties of treosulfan in miceExperimental Hematology, 2006